2.

Cumulative dose-related cardiac toxicity typically results from administration of

1.

doxorubicin

2.

bleomycin

3.

vincristine

4.

imatinib

5.

irinotecan

3.

Goserelin is used in treating advanced prostate cancer because of its ability to

1.

increase gonadotrophin secretion

2.

reduce gonadotrophin secretion

3.

block testosterone receptors

4.

activate estrogen receptors

5.

inhibit estrogen synthesis

4.

Vincristine inhibits mitosis of cancer cells at metaphase by

1.

inhibiting telomerase

2.

increasing tubulin degradation

3.

inhibiting synthesis of tubulin

4.

inhibiting polymerization of tubulin

5.

stabilizing microtubules

5.

Cytarabine is converted to an active triphosphate metabolite that inhibits

1.

DNA polymerase

2.

adenine deaminase

3.

dihydrofolate reductase

4.

telomerase

5.

thymidylate synthetase

6.

Folinic acid can be administered to counteract the toxic effects of

1.

fludarabine

2.

gemcitabine

3.

cytarabine

4.

fluorouracil

5.

methotrexate

7.

Reactive carbonium ions that attack guanine bases of DNA and lead to crosslinking of DNA strands are formed in the body from drugs such as

1.

cisplatin

2.

bleomycin

3.

doxorubicin

4.

etoposide

5.

cyclophosphamide